Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | KDM1B | Q8NB78 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29414007 | 1.00 | TNF (0.35) | TNFRIPK1KDM1AKCNH2KDM1B | |
| SCHEMBL29616362 | 0.81 | TNF (0.37) | TNFRIPK1HTR2AHTR2CHTR2B | |
| SCHEMBL3087235 | 0.81 | TNF (0.37) | TNFRIPK1HTR2AHTR2CHTR2B | |
| SCHEMBL31070219 | 0.79 | CYP3A4 (0.35) | KDM1AKCNH2KDM1B | |
| SCHEMBL2013956 | 0.79 | CYP3A4 (0.35) | KDM1AKCNH2KDM1B | |
| SCHEMBL9339526 | 0.79 | HTR2A (0.32) | TNFRIPK1HTR2AHTR2CHTR2B | |
| SCHEMBL31289362 | 0.77 | TNF (0.41) | TNFRIPK1HTR2AHTR2CHTR2B | |
| SCHEMBL2046247 | 0.77 | TNF (0.41) | TNFRIPK1HTR2AHTR2CHTR2B | |
| SCHEMBL17711300 | 0.77 | NOTUM (0.40) | KDM1AKCNH2KDM1B | |
| SCHEMBL30384989 | 0.77 | NOTUM (0.40) | KDM1AKCNH2KDM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4479022-A | ETHER, ALKALINE BASE CATALYST COMPLEXES | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1984-10-23 | — | — | US | claimed |
| US-12637461-B2 | Compounds for the activation of AMPK | PFIZER INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-12516046-B2 | 2-oxo-oxazolidine-5-carboxamides as NAV1.8 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-01-06 | — | — | US | disclosed |
| US-20250340548-A1 | KRAS G12C INHIBITORS | FRONTIER MEDICINES CORP (US) | 2025-11-06 | — | — | US | disclosed |
| US-12398154-B2 | Azaquinazoline pan-KRas inhibitors | Mirati Therapeutics, Inc. (US) | 2025-08-26 | — | — | US | disclosed |
| US-12291539-B2 | KRAS G12C inhibitors | FRONTIER MEDICINES CORPORATION (US) | 2025-05-06 | — | — | US | disclosed |
| EP-4501932-A2 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| US-20250019387-A1 | KRAS G12C INHIBITORS | FRONTIER MEDICINES CORPORATION | 2025-01-16 | — | — | US | disclosed |
| EP-3880208-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-11-20 | — | — | EP | disclosed |
| EP-4436571-A1 | SMALL MOLECULE INHIBITORS OF KRAS MUTATED PROTEINS | Merck Sharp & Dohme LLC (US) | 2024-10-02 | — | — | EP | disclosed |
| US-20020173501-A1 | Antimicrobial quinolones, their compositions and uses | THE PROCTER & GAMBLE COMPANY | 2002-11-21 | — | — | US | disclosed |
| US-6387928-B1 | BACTERICIDES; SIDE EFFECT REDUCTION | THE PROCTER & GAMBLE CO. | 2002-05-14 | — | — | US | disclosed |
| US-20020049192-A1 | Antimicrobial quinolones, their compositions and uses | THE PROCTER & GAMBLE COMPANY | 2002-04-25 | — | — | US | disclosed |
| US-6348624-B1 | TREATING 1-BROMO-2,4-DIFLUOROBENZENE WITH STRONG, NON-NUCLEOPHILIC BASE, REACTING WITH ELECTROPHILIC REAGENT, TREATING WITH ALKALI OR ALKALINE EARTH METAL OR ORGANOMETALLIC REAGENT AND CARBON DIOXIDE, OR FORMYLATING AND OXIDIZING | THE PROCTER & GAMBLE CO. | 2002-02-19 | — | — | US | disclosed |
| US-6329391-B1 | ANTIBIOTICS, BACTERICIDES USING QUINOLONES | THE PROCTER & GAMBLE CO. | 2001-12-11 | — | — | US | disclosed |
| EP-1045823-A1 | PROCESS FOR MAKING CERTAIN BENZOIC ACID COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 2000-10-25 | — | — | EP | disclosed |
| EP-1015445-A1 | ANTIMICROBIAL QUINOLONES, THEIR COMPOSITIONS AND USES | THE PROCTER & GAMBLE COMPANY (US) | 2000-07-05 | — | — | EP | disclosed |
| WO-1999035117-A1 | PROCESS FOR MAKING CERTAIN BENZOIC ACID COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 1999-07-15 | — | — | WO | disclosed |
| WO-1999014214-A1 | ANTIMICROBIAL QUINOLONES, THEIR COMPOSITIONS AND USES | THE PROCTER & GAMBLE COMPANY (US) | 1999-03-25 | — | — | WO | disclosed |
| US-4479022-A | ETHER, ALKALINE BASE CATALYST COMPLEXES | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1984-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049192-A1 | Antimicrobial quinolones, their compositions and uses | QARS1, TOP1, TOP2A | TNF 2977/4885RIPK1 4121/4885KDM1A 3454/4885 |
| US-12637461-B2 | Compounds for the activation of AMPK | PRKAG1, PRKAB1, PRKAA1 | TNF 4784/4885RIPK1 2036/4885KDM1A 3028/4885 |
| US-12291539-B2 | KRAS G12C inhibitors | KRAS, NRAS, HRAS | TNF 4729/4885RIPK1 1247/4885KDM1A 3144/4885 |
| US-20250340548-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | TNF 4729/4885RIPK1 1247/4885KDM1A 3144/4885 |
| US-20020173501-A1 | Antimicrobial quinolones, their compositions and uses | QARS1, TOP1, TOP2A | TNF 2977/4885RIPK1 4121/4885KDM1A 3454/4885 |
| US-20250019387-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | TNF 4729/4885RIPK1 1247/4885KDM1A 3144/4885 |
| US-12398154-B2 | Azaquinazoline pan-KRas inhibitors | KRAS, NRAS, HRAS | TNF 4239/4885RIPK1 728/4885KDM1A 1875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.